Will subdued market conditions impact Concord Biotech debut?

Anubhuti Mishra, equity research analyst at Swastika Investmart also said, "The upcoming listing of Concord Biotech is expected to be at a premium of around Rs 122 (16.46 percent) per share. This would mean that the shares could list at a price of around Rs 863 per share."Read more at:

1. Concord Biotech IPO to deliver a strong listing pop? Here's what grey market premium suggests - Business Today
2. Will subdued market conditions impact Concord Biotech debut? - Money Control
3. Concord Biotech IPO: Here’s what analyst says about listing - India Today